FDA Drug Recalls

Recalls / Class II

Class IID-0856-2017

Product

DORAMA-NEO (naphazoline hydrochloride) Eye wash, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-020-01

Affected lot / code info
Lot #: WXTZ, Exp. Sep 2019

Why it was recalled

Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

Recalling firm

Firm
Sato Pharmaceutical Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
20695 S Western Ave Ste 240, Torrance, California 90501-1834

Distribution

Quantity
14,325 bottles
Distribution pattern
US: Hawaii, Guam, Saipan, SPI

Timeline

Recall initiated
2017-02-16
FDA classified
2017-05-23
Posted by FDA
2017-05-31
Terminated
2018-03-13
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0856-2017. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: drug · FDA Drug Recalls